• Alemtuzumab (71) : LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age. https://www.lemtrada.com/
  • Amiselimod (1) : sg
  • Bexarotene (3) :
  • Bu Shen Yi Sui Capsules (5) : Bu Shen Yi Sui capsule (BSYSC) is a traditional Chinese herbal medicine.
  • Cladribine (1) :
  • COVID-19 (435) :
  • Evobrutinib (3) : sg
  • Ginsenoside Rg1 (4) : Ginsenoside Rg1 is being added as a category based on this paper https://pubmed.ncbi.nlm.nih.gov/35994846/
  • Gut microbiome (195) : Creating this as a category after reading this abstract https://www.msard-journal.com/article/S2211-0348(22)00671-X/fulltext
  • Kynurenine (10) : Kynurenine was added as a category based on this article: https://pubmed.ncbi.nlm.nih.gov/36004319/
  • Maresin-1 (1) : https://neurosciencenews.com/inflammation-lipid-ms-20501/
  • Metformin (12) :
  • Mobility (53) : Articles mentioning mobility or EDSS score
  • Natalizumab (207) :
  • Nuclear Medicine (5) : All articles matching nuclear medicine, molecular imaging, or $theranostic
  • Ocrelizumab (106) :
  • Oligodendrocytes (26) :
  • Physical therapy and Telerehabilitation (90) : Search terms: telerehabilitation, physical therapy, virtual reality, gamification, neurostimulation, cognitive training, spasticity, motor control. Suggested by Alejandro Carrabs
  • Simvastatin (1) :
  • Siponimod (24) : Siponimod (also known as BAF312 or Mayzent) is a tablet being developed for secondary progressive MS by Novartis Pharmaceuticals. It was licensed by the European Medicines Agency (EMA) on Monday 20 January 2020. https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/explore-treatments-in-trials/siponimod
  • Stem Cells (110) : Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
  • Tolebrutinib (1) : Based on the following article, this item was added to the Observatory page. > Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial Source [The Lancet](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00237-4/fulltext)
  • Ublituximab (3) : sg
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.